Abstract
Purpose
A number of studies on the relationship between xeroderma pigmentosum group G (XPG) polymorphisms and clinical outcomes in non-small cell cancer (NSCLC) have led to inconclusive results. This meta-analysis evaluates the predictive value of XPG polymorphisms on the treatment response rate and overall survival of patients with NSCLC.
Methods
To measure the correlative strength of the relationship between XPG polymorphisms and outcomes of patients with NSCLC, we searched electronic databases, including PubMed and China National Knowledge Infrastructure, to retrieve studies up to August 2016. We also employed pooled odds ratios (ORs) and hazard ratios (HRs) corresponding to 95% confidence intervals (95% CIs).
Results
Twelve studies involving 2877 patients with NSCLC were included: 8 studies involving 1473 patients examined the correlation between XPG polymorphisms and tumor response rate and 7 studies involving 2329 patients reported on the correlation of XPG polymorphisms with overall survival. None of the XPG His1104Asp(C>G)/His46His(C>T) polymorphisms exhibited a correlation with treatment response rate or overall survival. However, in a further stratified analysis by ethnicity, carriers of the 1104G allele were associated with good response among Asians in the homozygote model (GG vs. CC: OR = 1.57, 95% CI: 1.05–2.34, P = 0.027). Meanwhile, further stratified by ethnicity, His46His polymorphism was not associated with RR and OS in any genetic models.
Conclusions
No strong evidence was found to support the use of XPG polymorphisms as tumor response and prognostic factors of patients with NSCLC receiving a platinum-based treatment regimen, which is attributed to marginal association. Studies with large-scale and multiple ethnicities need to be conducted to verify the conclusion.
References
Torre LA, Siegel RL, Jemal A (2016) Lung cancer statistics. Adv Exp Med Biol 893:1–19. doi:10.1007/978-3-319-24223-1_1
Koinis F, Kotsakis A, Georgoulias V (2016) Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res 5(1):39–50. doi:10.3978/j.issn.2218-6751.2016.01.03
Amarasena IU, Chatterjee S, Walters JA, Wood-Baker R, Fong KM (2015) Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev 8:CD006849. doi:10.1002/14651858.CD006849.pub3
Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Ardine M, Barni S (2013) Platinum rechallenge in patients with advanced NSCLC: a pooled analysis. Lung cancer 81(3):337–342. doi:10.1016/j.lungcan.2013.06.022
Wei R, DeVilbiss FT, Liu W (2015) Genetic polymorphism, telomere biology and non-small lung cancer risk. J Genet Genom Yi chuan xue bao 42(10):549–561. doi:10.1016/j.jgg.2015.08.005
de Mello RA (2014) Genetic polymorphisms and non-small-cell lung cancer: future paradigms. Einstein 12 (4):524–526. doi:10.1590/S1679-45082014RB2906
Bowden NA (2014) Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett 346(2):163–171. doi:10.1016/j.canlet.2014.01.005
Qiu M, Yang X, Hu J, Ding X, Jiang F, Yin R, Xu L (2013) Predictive value of XPD polymorphisms on platinum-based chemotherapy in non-small cell lung cancer: a systematic review and meta-analysis. PloS one 8(8):e72251. doi:10.1371/journal.pone.0072251
Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, Matullo G (2006) XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol 164(4):297–302. doi:10.1093/aje/kwj189
Scherly D, Nouspikel T, Corlet J, Ucla C, Bairoch A, Clarkson SG (1993) Complementation of the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2. Nature 363(6425):182–185. doi:10.1038/363182a0
He C, Duan Z, Li P, Xu Q, Yuan Y (2013) Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer. Anticancer Drugs 24(3):300–305. doi:10.1097/CAD.0b013e32835bd6ce
Hanawalt PC (2001) Controlling the efficiency of excision repair. Mutat Res 485(1):3–13
Emmert S, Slor H, Busch DB, Batko S, Albert RB, Coleman D, Khan SG, Abu-Libdeh B, DiGiovanna JJ, Cunningham BB, Lee MM, Crollick J, Inui H, Ueda T, Hedayati M, Grossman L, Shahlavi T, Cleaver JE, Kraemer KH (2002) Relationship of neurologic degeneration to genotype in three xeroderma pigmentosum group G patients. J Invest Dermatol 118(6):972–982. doi:10.1046/j.1523-1747.2002.01782.x
Melis JP, van Steeg H, Luijten M (2013) Oxidative DNA damage and nucleotide excision repair. Antioxid Redox Signal 18(18):2409–2419. doi:10.1089/ars.2012.5036
Ito S, Kuraoka I, Chymkowitch P, Compe E, Takedachi A, Ishigami C, Coin F, Egly JM, Tanaka K (2007) XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients. Mol Cell 26(2):231–243. doi:10.1016/j.molcel.2007.03.013
Scharer OD (2008) Hot topics in DNA repair: the molecular basis for different disease states caused by mutations in TFIIH and XPG. DNA Repair 7 (2):339–344. doi:10.1016/j.dnarep.2007.10.007
Klungland A, Hoss M, Gunz D, Constantinou A, Clarkson SG, Doetsch PW, Bolton PH, Wood RD, Lindahl T (1999) Base excision repair of oxidative DNA damage activated by XPG protein. Mol Cell 3(1):33–42
Wen H, Feng CC, Fang ZJ, Xia GW, Jiang HW, Xu G, Huang XD, Ding Q (2013) Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers. Actas Urol Esp 37(5):259–265. doi:10.1016/j.acuro.2012.04.007
Negandhi AA, Hyde A, Dicks E, Pollett W, Younghusband BH, Parfrey P, Green RC, Savas S (2013) MTHFR Glu429Ala and ERCC5 His46His polymorphisms are associated with prognosis in colorectal cancer patients: analysis of two independent cohorts from Newfoundland. PloS One 8(4):e61469. doi:10.1371/journal.pone.0061469
Liu D, Wu J, Shi GY, Zhou HF, Yu Y (2014) Role of XRCC1 and ERCC5 polymorphisms on clinical outcomes in advanced non-small cell lung cancer. Genet Mol Res GMR 13 (2):3100–3107. doi:10.4238/2014.April.17.6
Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16
Yu Q, Han J, Pan J, Sheng L, Wu J, Huang H (2007) The relationship between the polymorphisms of gene XPG and MDR1 and the responsiveness of advanced non-sma ll cell lung cancer to platinum-based chem otherapy. Practical Journal of Cancer 3(22):252–256. doi:10.1002/ijc.10870 (Article Chinese)
Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, Consortium G, Eisen T, Houlston RS (2007) Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet 16(19):2333–2340. doi:10.1093/hmg/ddm190
Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z (2009) Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung cancer 65(2):230–236. doi:10.1016/j.lungcan.2008.11.014
Feng J, Sun X, Sun N, Qin S, Li F, Cheng H, Chen B, Cao Y, Ma J, Cheng L, Lu Z, Ji J, Zhou Y (2009) XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 41(5):429–435
Butkiewicz D, Rusin M, Sikora B, Lach A, Chorazy M (2011) An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer. Mol Biol Rep 38(8):5231–5241. doi:10.1007/s11033-010-0674-1
Jia XF, Liang J, Lv HY, Yao RY, Zhou F, Han Y (2011) Relationship between XPA and XPG polymorphisms and platinum-based chemotherapy outcomes in advanced non-small cell lung cancer. Progress Modern Biomed 9 (11):1718–1722. doi:10.1097/FPC.0b013e3280115e63. Article in Chinese.
Lv HY, Li QC, Wei HJ, Xiang JY, Yao RY, Liang J (2012) Relationship between GSTP1 and XPG genetic polymorphisms and survival of platinum-based chemotherapy in advanced non-small cell lung cancer patients. China Int Soc Cell 8(22):609–615. doi:10.1093/hmg/ddm351 (Article Chinese).
Zhang T, Sun J, Lv M, Zhang L, Wang X, Ren JC, Wang B (2013) XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy. Asian Pacific J Cancer Prev APJCP 14 (2):701–705
Yuli Y, Zhe S, Xia W, Siqing L, Zhenxuan W, Yu-Hua Z, Bing S, Jun-Wei C (2013) XPG is a novel biomarker of clinical outcome in advanced non-small-cell lung cancer. Pak J Med Sci 29(3):762–767
Jin ZY, Zhao XT, Zhang LN, Wang Y, Yue WT, Xu SF (2014) Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer. Genet Mol Res GMR 13 (3):7617–7625. doi:10.4238/2014.March.31.13
Sullivan I, Salazar J, Majem M, Pallares C, Del Rio E, Paez D, Baiget M, Barnadas A (2014) Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett 353(2):160–166. doi:10.1016/j.canlet.2014.07.023
Hu W, Pan J, Zhao P, Yang G, Yang S (2014) Genetic polymorphisms in XPG could predict clinical outcome of platinum-based chemotherapy for advanced non-small cell lung cancer. Tumour Biol J Int Soc Oncodev Biol Med 35(6):5561–5567. doi:10.1007/s13277-014-1732-4
Huang D, Zhou Y (2014) Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: a meta-analysis based on 44 studies. Biomed Rep 2(4):452–462. doi:10.3892/br.2014.282
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to declare.
Human participants
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Xiang, T., Kang, X., Gong, Z. et al. XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies. Cancer Chemother Pharmacol 79, 791–800 (2017). https://doi.org/10.1007/s00280-017-3280-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-017-3280-2